Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms

NCT04782830 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension. For this purpose, the investigators will use an activity monitor to determine the amount of time patients spend in the upright position (standing and walking; upright time) during 1 week of placebo (a pill with no active ingredients) and 1 week of their regular medication for orthostatic hypotension (midodrine or atomoxetine at their usual doses). Total upright time (i.e. tolerance to standing and walking) will be compared between placebo and active treatment to test the hypothesis that it can be used to assess the efficacy of the treatment for orthostatic hypotension and whether this outcome is superior to the assessment of symptoms using validated questionnaires.

Interventions

  • DEVICE Accelerometer
  • DRUG placebo pill
  • DRUG Midodrine or atomoxetine pill

Study Locations (1)

Tennessee

  • Autonomic Dysfunction Center/ Vanderbilt University Medical Center — Nashville

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2021-02-05
Est. Completion 2027-10-01
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04782830

The ClinicalTrials.gov registry entry for NCT04782830 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 695 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Multiple System Atrophy appearing as the primary indexed condition, and to 3 interventions — of which Accelerometer is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04782830 reports 1 study location spanning 1 distinct geographic area — top geographies include Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04782830 about?

NCT04782830 is a clinical study titled "Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms". The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension. For this purpose, the investigators will use an activity monitor to determine the amount of time patients spend in the upright position (standing a...

What is the current status of trial NCT04782830?

This trial is currently recruiting. It is a NA study. The enrollment target is 29 participants. The study started on 2021-02-05. Estimated completion is 2027-10-01.

What conditions does trial NCT04782830 study?

This clinical trial studies the following conditions: Multiple System Atrophy, Autonomic Failure, Pure Autonomic Failure, Orthostatic; Hypotension, Neurogenic, Orthostatic; Hypotension, Parkinsonism. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04782830?

The interventions under investigation include: Accelerometer (DEVICE), placebo pill (DRUG), Midodrine or atomoxetine pill (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04782830?

This trial is sponsored by Vanderbilt University Medical Center, which has 695 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04782830 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial